Acadia PharmaceuticalsACAD
ACAD
About: Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Employees: 654
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
138% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 29
137% more call options, than puts
Call options by funds: $18.4M | Put options by funds: $7.74M
67% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 5 (+2) [Q4]
51% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 72
25% more capital invested
Capital invested by funds: $2.38B [Q3] → $2.99B (+$604M) [Q4]
15% more funds holding
Funds holding: 255 [Q3] → 292 (+37) [Q4]
4.43% more ownership
Funds ownership: 93.45% [Q3] → 97.88% (+4.43%) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
36%
upside
Avg. target
$25
67%
upside
High target
$28
91%
upside
6 analyst ratings
4 positive
67%
2 neutral
33%
0 negative
0%
UBS Ashwani Verma 15% 1-year accuracy 3 / 20 met price target | 50%upside $22 | Buy Maintained | 28 Apr 2025 |
Needham Ami Fadia 18% 1-year accuracy 29 / 160 met price target | 91%upside $28 | Buy Reiterated | 8 Apr 2025 |
Morgan Stanley Jeffrey Hung 12% 1-year accuracy 3 / 26 met price target | 36%upside $20 | Equal-Weight Assumed | 7 Mar 2025 |
Cantor Fitzgerald Charles Duncan 27% 1-year accuracy 13 / 48 met price target | 91%upside $28 | Overweight Reiterated | 27 Feb 2025 |
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 111 / 353 met price target | 84%upside $27 | Buy Reiterated | 27 Feb 2025 |
Financial journalist opinion
Based on 3 articles about ACAD published over the past 30 days
Neutral
Business Wire
5 days ago
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be ac.
Neutral
Business Wire
2 weeks ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 172,637 shares of common stock and 64,791 restricted stock units (“RSUs”) to twenty-two new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees'.
Positive
Zacks Investment Research
2 weeks ago
Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Negative
Zacks Investment Research
1 month ago
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Neutral
Business Wire
1 month ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units (“RSUs”) to thirteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' em.
Neutral
Business Wire
1 month ago
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual Healthcare Conference Fireside Chat: Monday, April 7, 2025 at 10:15 a.m. Eastern Time Live webcasts of each fireside chat wi.
Neutral
Business Wire
1 month ago
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age an.
Negative
Zacks Investment Research
1 month ago
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)
Acadia Pharmaceuticals (ACAD) came out with fourth-quarter earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago.
Negative
Zacks Investment Research
1 month ago
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
Neutral
Business Wire
1 month ago
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
SAN DIEGO & COPENHAGEN, Denmark--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study (EUCT: 2024-514514-12-00) of ACP-711, formerly SAN711, in healthy volunteers. In the study, ACP-711 was safe and generally well tolerated across all dosing cohorts. There were no serious adverse events, and all participants completed the study. Most.
Charts implemented using Lightweight Charts™